

# RESEARCH TO PRACTICE



**June 28**

**Wednesday**

**12:00 – 1:00 PM EST/EDT**

[learn.unclcn.org/06282023](https://learn.unclcn.org/06282023)




**Available in one month**

[learn.unclcn.org/spoc](https://learn.unclcn.org/spoc)



## Lymphoma Management in North Carolina: Updates for 2023



**Natalie Grover, MD**

*Assistant Professor of Medicine*

*Clinical Director, Cellular Therapy Program*

*Leader, Cell Therapy POD*

UNC Lineberger Comprehensive Cancer Center

UNC School of Medicine

University of North Carolina at Chapel Hill

### Webinar Description

Natalie Grover, MD, will review some of the recent advances in the treatment of lymphoma, including the incorporation of novel targeted agents in the frontline treatment of diffuse large B cell lymphoma and Hodgkin lymphoma, the use of CAR-T cell therapy in second-line treatment in diffuse large B cell lymphoma, and recently approved drugs by the FDA for lymphoma.

### Learning Objectives

- Discuss the use of polatuzumab vedotin in the frontline treatment of diffuse large B cell lymphoma
- Identify patients with diffuse large B cell lymphoma who are eligible for CAR-T cell therapy
- Discuss the use of brentuximab vedotin in the frontline treatment of Hodgkin lymphoma

This program co-provided with **UNC Digital and Lifelong Learning**

### UNCLCN SITES

**UNCLCN Website**

[unclcn.org](https://unclcn.org)

**UNCLCN Learning Portal**

[learn.unclcn.org](https://learn.unclcn.org)

**Upcoming Live Webinars**

[learn.unclcn.org/live-webinars](https://learn.unclcn.org/live-webinars)

### DISCLOSURE STATEMENT

**Activity Directors:** This activity has been planned and implemented under the sole supervision of the Course Director, William A Wood, MD, MPH, in association with the UNC Office of Continuing Professional Development (CPD). The course director and CPD staff have no relevant financial relationships with ineligible companies as defined by the ACCME.

**Speaker(s):** The speaker holds stock in Sangamo Therapeutics and receives consulting fees from Novartis. The speaker received consulting fees from ADC Therapeutics (ended 3/23), Caribou Biosciences (ended 2/23), Genentech (ended 12/22), Kite (ended 3/23), and Seagen (ended 6/22). These financial relationships have been mitigated through slide review by UNC CPD.

### ACCREDITATION

**NCPD/CNE:** The University of North Carolina at Chapel Hill is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. To successfully complete this program and be awarded 1 contact hour you must attend at least 50 minutes of the seminar and complete the online evaluation.

**ACPE:** The UNC Eshelman School of Pharmacy Postgraduate/Continuing Education (PGCE) Program provides accredited professional educational activities for pharmacists and pharmacy technicians. The Eshelman School of Pharmacy of the University of North Carolina at Chapel Hill designates this live activity for a maximum of 1.0 ACPE Credit(s).

**ASRT:** The American Registry of Radiologic Technologists (ARRT) is a leading credentialing organization that recognizes qualified individuals in medical imaging, interventional procedures, and radiation therapy. This activity is worth 1 credit hour and is pending approval by the ASRT.

**CME:** The School of Medicine of the University of North Carolina at Chapel Hill is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The School of Medicine of the University of North Carolina at Chapel Hill designates this live internet activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)<sup>™</sup>. Physicians should claim only the credit commensurate with the extent of their participation in the activity.